REXCEL EGYPT COMPANY (L.L.C) FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2018 TOGETHER WITH AUDITOR'S REPORT

REXCEL EGYPT COMPANY (L.L.C.) Financial Statements For the year ended 31 March 2018

Table of Contents

	Page
Auditor's Report on the Financial Statements	2
Statement of Financial Position	3
Statement of Profit or Loss	4
Statement of Comprehensive Income	5
Statement of Changes in Equity	6
Statement of Cash Flows	7
Notes to the Financial Statements	8 – 23



Allied for Accounting & Auditing
Ragnes, Hamoods, Interbook, Tageldon & EH-Klanv
P O Box 20 Kattameya
Rama Tower
Ring Road, Zone #10A
Kattameya, Cairo, Egypt

Tel: +202 2726 0260 Fax: +202 2726 0100 Cairo office@eg.ey.com. ey.com/mena

Translation of Auditor's report Originally issued in Arabic

AUDITOR'S REPORT

TO THE STOCKHOLDERS OF REXCEL EGYPT COMPANY (L.L.C.)

Report on the Financial Statements

We have audited the accompanying financial statements of REXCEL EGYPT COMPANY (L.L.C.), represented in the statement of Financial position as of 31 March 2018, and the related statements of profit or loss, comprehensive income, changes in equity and cash flows for the year then ended, and a summary of significant accounting policies and other explanatory notes.

Management's Responsibility for the Financial Statements

These financial statements are the responsibility of the Company's Management, as Management is responsible for the preparation and fair presentation of the financial statements in accordance with Egyptian Accounting Standards and applicable Egyptian laws. Management responsibility includes: designing, implementing and maintaining internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. This responsibility also includes selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

Our responsibility is to express an opinion on those financial statements based on our audit. We conducted our audit in accordance with Egyptian Standards on Auditing and applicable Egyptian laws. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance that the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's professional judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on those financial statements.

Opinion

In our opinion, the financial statements referred to above, give a true and fair view, in all material respects, of the financial position of REXCEL EGYPT COMPANY (L.L.C.), as of 31 March 2018, and of its financial performance and its cash flows for the year then ended in accordance with Egyptian Accounting Standards and the related applicable Egyptian laws and regulations.



Report on other legal and regulatory requirements

The Company maintains proper accounting records that comply with the laws and the Company's articles of association and the financial statements agree with the Company's records. The physical inventory count was undertaken by the Company's Management in accordance with the proper norms.

We draw attention that the Company's losses exceeded the capital which necessitates calling an Extraordinary General Assembly Meeting to decide on the continuity of the Company in accordance with the provisions of Law no.159 of 1981.

The financial information included in the General Managers' Report, prepared in accordance with Law No. 159 of 1981 and its executive regulation, is in agreement with the books of the Company insofar as such information is recorded therein.

STATEMENT OF FINANCIAL POSITION As of 31 March 2018

Assets LE LE Noncurrent assets Fixed assets (3)
Current assets
Total noncurrent assets Current assets Inventory (4) 93,718 465,949 Trade and notes receivable (5) - 201,465 Prepayments and other receivables (6) 639,950 710,825 Cash at banks (7) 787,496 1,833,680 Total current assets 1,521,164 3,211,919 TOTAL ASSETS 1,521,164 3,211,919 EQUITY AND LIABILITIES Equity Paid up capital (12) 240,000 240,000 Legal reserve 240,000 240,000 (Accumulated losses) (3,562,965) (1,362,346) (Losses) for the year (2,009,790) (2,200,619) Total equity (5,092,755) (3,082,965)
Inventory
Trade and notes receivable (5) - 201,465 Prepayments and other receivables (6) 639,950 710,825 Cash at banks (7) 787,496 1,833,680 Total current assets 1,521,164 3,211,919 TOTAL ASSETS 1,521,164 3,211,919 EQUITY AND LIABILITIES Equity Paid up capital (12) 240,000 240,000 Legal reserve 240,000 240,000 (Accumulated losses) (3,562,965) (1,362,346) (Losses) for the year (2,009,790) (2,200,619) Total equity (5,092,755) (3,082,965)
Prepayments and other receivables (6) 639,950 710,825 Cash at banks (7) 787,496 1,833,680 Total current assets 1,521,164 3,211,919 TOTAL ASSETS 1,521,164 3,211,919 EQUITY AND LIABILITIES 240,000 240,000 Legal reserve 240,000 240,000 (Accumulated losses) (3,562,965) (1,362,346) (Losses) for the year (2,009,790) (2,200,619) Total equity (5,092,755) (3,082,965)
Cash at banks (7) 787,496 1,833,680 Total current assets 1,521,164 3,211,919 TOTAL ASSETS 1,521,164 3,211,919 EQUITY AND LIABILITIES Equity Paid up capital (12) 240,000 240,000 Legal reserve 240,000 240,000 (240,000 (Accumulated losses) (3,562,965) (1,362,346) (Losses) for the year (2,009,790) (2,200,619) Total equity (5,092,755) (3,082,965)
Total current assets TOTAL ASSETS 1,521,164 3,211,919 EQUITY AND LIABILITIES Equity Paid up capital Legal reserve (Accumulated losses) (Losses) for the year Total equity LIABILITIES (12) 240,000 240,000 240,000 (3,562,965) (1,362,346) (2,009,790) (2,200,619) (5,092,755) (3,082,965)
TOTAL ASSETS EQUITY AND LIABILITIES Equity Paid up capital Legal reserve (Accumulated losses) (Losses) for the year Total equity LIABILITIES 1,521,164 3,211,919 3,211,919 3,211,919 1,521,164 3,211,919 1,521,164 3,211,919 1,521,164 3,211,919 1,521,164 3,211,919 1,521,164 3,211,919 1,521,164 3,211,919 1,521,164
EQUITY AND LIABILITIES Equity Paid up capital Legal reserve (Accumulated losses) (Losses) for the year Total equity LIABILITIES (12) 240,000 240,000 240,000 (240
Equity Paid up capital (12) 240,000 240,000 Legal reserve 240,000 240,000 (Accumulated losses) (3,562,965) (1,362,346) (Losses) for the year (2,009,790) (2,200,619) Total equity (5,092,755) (3,082,965)
Paid up capital (12) 240,000 240,000 Legal reserve 240,000 240,000 (Accumulated losses) (3,562,965) (1,362,346) (Losses) for the year (2,009,790) (2,200,619) Total equity (5,092,755) (3,082,965)
Legal reserve 240,000 240,000 (Accumulated losses) (3,562,965) (1,362,346) (Losses) for the year (2,009,790) (2,200,619) Total equity (5,092,755) (3,082,965)
Legal reserve 240,000 240,000 (Accumulated losses) (3,562,965) (1,362,346) (Losses) for the year (2,009,790) (2,200,619) Total equity (5,092,755) (3,082,965)
(Losses) for the year Total equity (2,009,790) (2,200,619) (5,092,755) (3,082,965)
Total equity (5,092,755) (3,082,965) LIABILITIES
LIABILITIES
Non-current liabilities
Due to related parties - long term (11) 2,173,000 2,173,000
Total non-current liabilities 2,173,000 2,173,000
Current liabilities
Provisions (8) 162,399 159,883
Trade payable 9,316
Due to related parties (11-16) 3,043,878 3,327,438
Accrued expenses and other payables (9) 1,230,173 625,247
Total current liabilities 4,440,919 4,121,884
TOTAL LIABILITIES 6,613,919 6,294,884
TOTAL LIABILITIES AND EQUITY 1,521,164 3,211,919

Financial Manager

Parmesh Adarkar

General Manager

Dr. Hany Mashaal

- Auditor's report "attached".

⁻ The accompanying notes from (1) to (18) are an integral part of these financial statements.

STATEMENT OF PROFIT OR LOSS For The Year Ended 31 March 2018

	Note	31/3/2018 LE	31/3/2017 LE
		Liki	LL
Sales	(13)	204,680	3,802,606
Sales returns	(13)	(915,728)	(653,312)
Allowable discounts	(13)	-	(926,481)
Allowable discounts - sales returns	(13)	202,114	-
Cost of sales	(14)	(566,690)	(644,926)
Cost of sales - sales returns	(14)	99,840	-
GROSS PROFIT		(975,784)	1,577,887
Selling and marketing expenses		(302,287)	(1,616,832)
General and administrative expenses		(554,263)	(1,301,742)
Provisions	(8)	(2,516)	(61,178)
Impairment in value of accounts receivable	(5)	(63,194)	(12,573)
Reversal of Impairment in value of accounts receivable	333	5,312	
Foreign exchange differences		32,165	(594,590)
Finance expenses		(220,318)	(226,270)
Other income		71,095	34,679
(LOSSES) BEFORE INCOME TAXES		(2,009,790)	(2,200,619)
Income taxes	(10)	-	-
(LOSSES) FOR THE YEAR		(2,009,790)	(2,200,619)

Financial Manager

General Manager

Parmesh Adarkar

Dr. Hany Mashaal

⁻ The accompanying notes from (1) to (18) are an integral part of these financial statements.

STATEMENT OF COMPREHENSIVE INCOME

For The Year Ended 31 March 2018

Notes	31/3/2018 LE	31/3/2017 LE
LOSSES FOR THE YEAR	(2,009,790)	(2,200,619)
OTHER COMPREHENSIVE INCOME		
TOTAL COMPREHENSIVE INCOME	(2,009,790)	(2,200,619)

⁻ The accompanying notes from (1) to (18) are an integral part of these financial statements.

STATEMENT OF CHANGES IN EQUITY For The year ended 31 March 2018

the .		(2,200,619	(3,082,965)	(2,009,790)	(5,092,755)
(Losses for the year)	(216,592)	(2,200,619)	(2,200,619) 2,200,619	(2,009,790)	(2,009,790)
(Accumulated losses) LE	(1,145,754)	(270,272)	(1,362,346) (2,200,619)	1	(3,562,965)
Legal reserve LE	240,000	1 1	240,000	1	240,000
Capital LE	240,000		240,000	1	240,000

STATEMENT OF CASH FLOWS For The year ended 31 March 2018

Cash Flows From Operating Activities	Note	31/3/2018 LE	31/3/2017 LE
(Losses) before income taxes		(2,009,790)	(2,200,619)
Impairment in value of inventory	(4)	591,822	248,918
Reversal of Impairment in value of inventory	(4)	(89,330)	(58,739)
Impairment in value of accounts receivables	(5)	63,194	12,573
Reversal of Impairment in value of accounts receivables	(5)	(5,313)	
Provisions	(8)	2,517	61,178
		(1,446,900)	(1,936,689)
Change in inventory	(4)	(130,262)	22,233
Change in trade and notes receivable	(5)	143,583	187,009
Change in due from related parties			6,220,178
Change in prepayments and other receivables	(6)	70,875	275,832
Change in trade and notes payable		(4,847)	(11,722)
Change in due to related parties	(11)	(283,560)	(5,525,754)
Change in accrued expenses and other payables	(9)	604,927	172,572
Cash Flows (Used in) Operating Activities	45 610	(1,046,184)	(596,341)
Provisions used	(4)	-	(48,843)
Net Cash Flows (used in) Operating Activities		(1,046,184)	(645,184)
Net change in cash and cash equivalents-during the year		(1,046,184)	(645,184)
Cash and cash equivalent - beginning of the year		1,833,680	2,478,864)
Cash and cash equivalent - end of the year	(7)	787,496	1,833,680

⁻ The accompanying notes from (1) to (18) are an integral part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

1 BACKGROUND

Rexcel Egypt (L.L.C.) is an Egyptian Limited Liability Company was established under the Egyptian Law no. 159 of 1981 and its executive regulation.

The company's duration is 25 years starting from the date of registration in the commercial registry.

The company was located at 3 Ahmed Nessim St., Giza, Egypt.

According to the Extraordinary General Assembly dated 31 December 2016, the Company's shareholders approved the change of the main office location to be number 47 street number 270, Albasaten, New Maadi

The company is registered in the commercial registry under no. 102709 on August 6, 1998. The company's legal domicile is in Cairo - Arab Republic of Egypt.

According to the Extraordinary general assembly dated 10 December 2013 the financial year end was changed from 31 December to 31 March for each year.

The principal activities of the company are:

- Manufacturing, trading, selling and distributing of all types of pharmaceutical and chemical products, and its related raw materials.
- Construction and operation of factories for production of all types of pharmaceutical and chemical products.
- The company has the right to import equipment, machines, tools, and all raw materials concerning pharmaceutical & chemical products that help the company achieve its purposes.
- 4. Export, import and Commercial agencies

The company undertakes its activities in compliance with applicable regulatory laws and regulations provided that they obtain necessary licenses as applicable.

2 SIGNIFICANT ACCOUNTING POLICIES

2-1 BASIS OF PREPARATION

The financial statements are prepared in accordance with the going concern and historical cost basis.

The financial statements are prepared and presented in Egyptian pound, which is the Company's functional currency.

STATEMENT OF COMPLIANCE

The financial statements of the company have been prepared in accordance with the Egyptian accounting standards and the applicable laws and regulations.

The accounting policies adopted this year are consistent with those of the previous year.

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

2-2 SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES

The preparation of these financial statements requires management to make judgments and estimates that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures and the disclosure of contingent liabilities at the reporting date. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the assets or liabilities affected in future periods.

Estimates and their underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised.

The key judgements and estimates that have a significant impact on the financial statement of the Company are discussed below:

2-2-1 Judgments

Revenue recognition for sale of goods

In making their judgment, management considered the detailed criteria for the recognition of revenue from the sale of goods as set out in EAS 11 Revenue, and, in particular, whether the significant risks and rewards of ownership of the goods have passed to the buyer, which is usually upon the delivery of the goods and the issuance of an invoice.

2-2-2 Estimates

Impairment of trade and other receivables

An estimate of the collectible amount of trade and other receivables is made when collection of the full amount is no longer probable. For individually significant amounts, this estimate is performed on an individual basis. Amounts which are not individually significant, but are past due, are assessed collectively and a provision is applied according to the length of time past due, based on historical recovery rates.

Useful lives of fixed assets

The Company's management determines the estimated useful lives of its fixed assets for calculating depreciation. This estimate is determined after considering the expected usage of the asset or physical wear and tear. The management periodically reviews the estimated useful lives and the depreciation method to ensure that the method and the period of depreciation are consistent with the expected pattern of economic benefits from these assets.

Taxes

The Company is subject to income taxes in Egypt. Significant judgment is required to determine the total provision for current and deferred taxes. The Company establishes provision, based on reasonable estimates, for possible consequences of audits by the tax authorities in Egypt. The amount of such provision is based on various factors, such as experience of previous tax audits and different interpretations of tax regulations by the Company and the responsible tax authority. Such differences of interpretations may be on a wide variety of issues depending on the conditions prevailing in Egypt.

Deferred tax assets are recognised for unused accumulated tax losses to the extent that it is probable that taxable profits will be available against which the losses can be utilised. Significant management judgement is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

Impairment of non-financial assets

The Company assesses whether there are any indicators of impairment for all non-financial assets at each reporting date. The non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. When value in use calculations are undertaken, management estimates the expected future cash flows from the asset or cash-generating unit and chooses a suitable discount rate in order to calculate the present value of those cash flows.

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

2-3 SUMMARY SIGNIFICANT ACCOUNTING POLICIES

2-3-1 Foreign currency translation

Transactions in foreign currencies are initially recorded using the exchange rates prevailing that on the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are retranslated using the exchange rates prevailing at the statement of financial position date. All differences are recognized in the statement of profit or loss.

Nonmonetary items that are measured at historical cost in foreign currencies are translated using the exchange rates prevailing at the date of the initial recognition.

Nonmonetary items measured at fair value in a foreign currency are translated using the exchange rates prevailing at the date when the fair value is determined.

2-3-2 Fixed assets

Fixed assets are stated at historical cost net of accumulated depreciation and accumulated impairment losses. Such cost includes the cost of replacing part of the building, plant, and equipment when that cost is incurred, if the recognition criteria are met. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the building, plant, and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognized in statement of profit or loss as incurred.

Depreciation of an asset begins when it is in the location and condition necessary for it to be capable of operating in the manner intended by management, and is computed using the straight-line method according to the estimated useful life of the asset as follows:

Machinery and equipment

Years 3 - 5

Fixed assets are derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognizing of the asset is included in the statement of profit or loss when the asset is derecognized.

The assets residual values, useful lives and methods of depreciation are reviewed at each financial year end.

The Company assesses at each statement of financial position date whether there is an indication that fixed assets may be impaired. Where the carrying amount of an asset exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. Impairment losses are recognized in the statement of profit or loss.

A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, or the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the statement of profit or loss.

2-3-3 Inventory

Inventory is valued at the lower of cost (using the moving average method) or net realizable value.

Net realizable value is the estimated selling price in the ordinary course of business less estimated costs of completion and the estimated costs necessary to make the sale.

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

The amount of any write down of inventories to net realizable value shall be recognized in cost of sales in the statement of profit or loss in the period the write down or loss occurs. The amount of any reversal of any write down of inventories, arising from an increase in net realizable value, shall be recognized as reduction of cost of sales in the statement of profit or loss in the period in which the reversal occurs.

2-3-4 Accounts receivable and other receivables

Accounts receivable and other receivables are stated at original invoice amount net of any impairment losses.

Impairment losses are measured as the difference between the receivables carrying amount and the present value of estimated future cash flows. The impairment loss is recognized in the statement of profit or loss. Reversal of impairment is recognized in the statement of profit or loss in the period in which it occurs.

2-3-5 Accounts and notes payable, accrued expenses and other payables

Liabilities are recognised for amounts to be paid in the future for goods or services received, whether billed by the supplier or not.

2-3-6 Provisions

Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources representing economic benefits will be required to settle the obligation, and reliable estimate of the amount of the obligation can be made. Provisions are reviewed at each statement of financial position date and adjusted to reflect the best estimate.

Where the effect of the time value of money is material, the amount of a provision should be the present value of the expected expenditures required to settle the obligation. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance expense.

2-3-7 Social insurance

The Company makes contributions to the Social Insurance Authority calculated as a percentage of the employees' salaries. The Company's obligations are limited to these contributions, which are expensed when due.

2-3-8 Employees' retirements benefits

The company contributes to the social insurance scheme for the benefits of its employees in pursuance of the Social Insurance Law No. 79 of 1975 as amended. Contributions are charged to expenses as incurred.

2-3-9 Legal reserve

According to the Company's articles of association, 10% of the net profits of the year is transferred to the legal reserve until this reserve reaches 100% of the issued capital. The reserve is used upon a decision from the general assembly meeting based on the proposal of the management.

2-3-10 Borrowings

Borrowings are initially recognized at the value of the consideration received. Amounts maturing within one year are classified as current liabilities, unless the Company has the right to postpone the settlement for a period exceeding one year after the statement of financial position date, then the loan balance should be classified as non-current liabilities.

After initial recognition, interest bearing loans and borrowings are subsequently measured at amortized cost using the effective interest rate method. Gains and losses are recognized in the statement of profit or loss when the liabilities are derecognized as well as through the effective interest rate method amortization process.

Amortized cost is calculated by taking into account any discount or premium on acquisition and fee or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included in finance expenses in the statement of profit or loss.

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

2-3-11 Income taxes

Income tax is calculated in accordance with the Egyptian tax law.

Current income tax

Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the tax authority.

Deferred income tax

Deferred income tax is recognized using the liability method on temporary differences between the amount attributed to an asset or liability for tax purposes (tax base) and its carrying amount in the statement of financial position (accounting base) using the applicable tax rate.

Deferred tax asset is recognized when it is probable that the asset can be utilized to reduce future taxable profits and the asset is reduced by the portion that will not create future benefit.

Current and deferred tax shall be recognized as income or an expense and included in the statement of profit or loss for the period, except to the extent that the tax arises from a transaction or an event which is recognized, in the same or a different period, directly in equity.

2-3-12 Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.

Revenue is measured at the fair value of the consideration received, excluding discounts, rebates, and sales taxes or duty.

The following specific recognition criteria must also be met before revenue is recognized:

Sale of goods

Revenue from the sale of goods is recognized when the significant risks and rewards of ownership of the goods have been transferred to the buyer, usually on delivery of the goods.

Interest income

Interest income is recognized on the basis of the proportion of time taking into account the effective rate of return on the asset.

2-3-13 Expenses

All operating expenses are accounted for including general and administrative costs, and are all included in the statement of profit or loss for the period in which they are incurred.

Some administrative, general and marketing are divided between Sun Pharma Egypt Ltd. and Rexcel Egypt by average of 99% and 1% respectively.

These expenses serve both companies according to present agreements.

2-3-14 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of a qualifying asset that necessarily takes a substantial period to get ready for its intended use or sale are capitalized as part of the cost of the respective assets. All other borrowing costs are expensed in the period they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

2-3-15 Related party transactions

Related parties represent associated companies, major shareholders, directors and key management personnel of the Company, and entities controlled, jointly controlled or significantly influenced by such parties. Pricing policies and terms of these transactions are approved by the board of directors.

2-3-16 Contingent Liabilities and Assets

Contingent liabilities are not recognized in the financial statements. They are disclosed unless the possibility of an outflow of resources embodying economic benefits is remote.

A contingent asset is not recognized in the financial statements but disclosed when an inflow of economic benefits is probable.

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

2-3-17 Fair value measurement

For assets traded in an active market, fair value is determined by reference to quoted market bid prices.

The fair value of interest-bearing items is estimated based on discounted cash flows using interest rates for items with similar terms and risk characteristics.

For unquoted assets, fair value is determined by reference to the market value of a similar asset or is based on the expected discounted cash flows.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 Fair value measurements are those derived from quoted prices in an active market (that are unadjusted) for identical assets or liabilities.
- Level 2 Fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 Fair value measurements are those derived from valuation techniques that include inputs for the
 asset or liability that are not based on observable market data (unobservable inputs).

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

2-3-18 Impairment

Impairment of financial assets

The Company assesses at each statement of financial position date whether there is any objective evidence that a financial asset or a group of financial assets is impaired. A financial asset or a group of financial assets is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events that has occurred after the initial recognition of the asset and has an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated.

Impairment of non financial assets

The Company assesses at each statement of financial position date whether there is an indication that an asset may be impaired. Where the carrying amount of an asset or cash-generating unit (CGU) exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. Impairment losses are recognized in the statement of profit or loss.

A previously recognized impairment loss is only reversed if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the statement of profit or loss.

2-3-19 Statement of cash flows

The statement of cash flows is prepared using the indirect method.

2-3-20 Cash and cash equivalent

For the purpose of preparing the statement of cash flows, the cash and cash equivalent comprise cash on hand, current accounts with banks and time deposits maturing within three months less bank credit balances.

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

2-3-21 SEGMENT INFORMATION

Currently the Company's main business segment is manufacturing, trading, selling and distributing of all types of pharmaceutical and chemical products, and its related raw materials. The company's revenues during the year ended 31 March 2018 were reported under one segment in the financial statements.

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

3 FIXED ASSETS

	Machinery and Equipment	Total
	LE	LE
Cost		
As of 31 March 2017	209,518	209,518
As of 31 March 2018	209,518	209,518
Accumulated depreciation		
As of 31 March 2017	(209,518)	(209,518)
As of 31 March 2018	(209,518)	(209,518)
Net book value as of 31 March 2018	2	_
Net book value as of 31 March 2017	-	-

The Machinery and Equipment are fully depreciated and still being used in operations.

4 INVENTORY

	31/3/2018	31/3/2017
	LE	LE
Raw and packing materials	72,097	148,280
Finished Goods	503,040	504,049
Expired Goods	287,498	351,881
	862,635	1,004,210
Impairment in value of inventory - slow moving items	(481,419)	(186,380)
Impairment in value of inventory - expired good	(287,498)	(351,881)
	93,718	465,949

- The amount of impairment in value/reversal of impairment in value of inventory was included in the cost of sales (note 14).
- Movement of impairment in value of inventory is as follows:

	Impairment in value of inventory- slow moving	Impairment in value inventory - expired goods	Total
	LE	LE	LE
Balance as of 1 April 2016 Charged during the year Used during the year No longer required	174,370 65,590 (12,153) (41,427)	185,865 183,328 - (17,312)	360,235 248,918 (12,153) (58,739)
Balance as of 31 March 2017 Charged during the year Used during the year No longer required	186,380 373,670 (78,631)	351,881 218,152 (271,837) (10,699)	538,261 591,822 (271,837) (89,330)
Balance as of 31 March 2018	481,419	287,498	768,916

REXCEL EGYPT COMPANY (L.L.C.)

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

5

5	TRADE AND NOTES RECEIVABLE		
		31/3/2018	31/3/2017
		LE	LE
	Trade receivable	99,558	53,587
	Notes receivable	-	189,554
		99,558	243,141
	Impairments in value of trade and notes receivable	(99,558)	(41,676)
			201,465
	Movement of impairment in value of accounts and notes receivables is	s as follows:	
		31/3/2018	31/3/2017
		LE	LE
	Beginning balance	41,676	29,103
	Charged	63,194	12,573
	No longer required	(5,312)	-
	Ending balance	(99,558)	(41,676)
6	PREPAYMENTS AND OTHER RECEIVABLES		
		31/3/2018	31/3/2017
		LE	LE
	Employees' advances and imprests	830	106,454
	Advances to suppliers	54,303	25,872
	Tax authority - withholding taxes	576,250	575,729
	Deposits with others	3,600	3,600
	Other debit balances	5,797	5,000
		640,780	711,655
	Impairment in value of other debit balances	(830)	(830)
		639 950	710,825
7	CASH AT BANKS		
		31/3/2018	31/3/2017
		LE	LE
	a) Local Currency		DE
	Current accounts	773,329	1,818,890
		773,329	1,818,890
	b) Foreign currency	50 CONTROL CON	
	Current accounts	14,167	14,790
		14,167	14,790
		787,496	1,833,680

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

8 PROVISIONS

	31/3/2018	31/3/2017
	LE	LE
Beginning balance	159,883	147,548
Charged during the year	2,516	61,178
Used during the year	-	(48,843)
Ending balance for the year	162,399	159,883
9 ACCRUED EXPENSES AND OTHER PAYABLES		
	31/3/2018	31/3/2017
	LE	LE
Accrued expenses	676,173	546,404
Tax authority – withholding tax	68,486	69,378
Tax authority – salaries tax	1,660	1,299
Social insurance Authority	3,959	4,773
Medical professional stamp	180	933
Other credit Balances	-	2,460
Accounts receivable - Sales return	479,715	
	1,230,173	625,247
10 INCOME TAX		
The state of the s	31/3/2018	31/3/2017
	LE	LE
Income tax payable		
moone tax payable		
		-
Reconciliation of effective tax rate		
	31/3/2018	31/3/2017
	LE	LE
Losses before income taxes	(2,009,790)	(2,200,619)
Interest expenses	126,308	127,541
Impairment in value of inventory	591,822	248,918
Provision	2,516	61,178
Impairment in value of account receivables	63,194	12,573
Provision for sales return	-	35,745
Foreign exchange differences – unrealized	(26,683)	594,590
Reversal of impairment in value of inventory Inventory provision used	(94,643)	(58,739)
Non-deductible expenses	(264,325)	17.00
127	(375.700)	17,391
Foreign exchange differences realized - from prior year	(375,786)	(15,127)
Taxable (losses)	(1,987,387)	(1,176,549)

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

11 DUE FROM / TO RELATED PARTIES

Due to related parties

P		
	31/3/2018	31/3/2017
	LE	LE
Current		
Sun Pharmaceutical Industries Limited (India)	632,455	1,317,337
Sun Pharma Egypt Limited	2,392,711	1,974,488
Sun Pharma Egypt Limited - (Loan accrued interest)	18,712	35,613
	3,043,878	3,327,438
Non Current		
Sun Pharma Egypt Limited (L.L.C) - (long term loan) *	2,173,000	2,173,000
	2,173,000	2,173,000

^{*}This amount represents a loan granted from Sun Pharma Egypt Limited (L.L.C) with an amount of L.E. 1,650,000 as per the contract dated 28 December 2009, with an annual fixed interest rate of 10%, and another loan amounted to L.E. 523,000 as per the contract dated June 2010, with an annual fixed interest rate of 10%.

12 CAPITAL

The company's authorized capital amounted to L.E 240,000 while the issued and paid up capital of the company amounts to L.E 240,000 divided over 2400 quotas of par value L.E 100 each.

	Number of quotas	LE	Percentage
Sarwat Girgis Abdel Shahid	1,200	120,000	50%
Ibrahim Wassim Shalaby	1,080	108,000	45%
Ola Abdel Kader Mohamed	60	6,000	2.5%
Ahmed Mohamed Faried Elmeligy	60	6,000	2.5%
	2,400	240,000	100%

The Extra Ordinary General Assembly meeting held on 31 January 2016 approved the selling of Ibrahim Wassim Shalaby quota to Hany Ibrahim El-Hussini Osman .and amendment of article 5 of the company's statutes as follows:

Number of quotas	LE	Percentage
1,200	120,000	50%
1,080	108,000	45%
60	6,000	2.5%
60	6,000	2.5%
2,400	240,000	100%
	1,200 1,080 60 60	1,200 120,000 1,080 108,000 60 6,000 60 6,000

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

13 SALES

LE 204,680	LE 3,802,606
(915,728)	(653,312) (926,481)
(508,934)	2,222,813
	202,114 (508,934)

14 COST OF SALES

	31/3/2018	31/3/2017
	LE	LE
Cost of goods sold	-	361,874
Cost of goods sold returns	99,840	-
Other production expense	(64,198)	73,170
Product registration charges	-	16,700
Impairment in value of inventory (expired and slow moving) (Note 4)	(591,822)	248,918
Reversal of impairment in value of inventory (Note 4)	89,330	(58,739)
Other expenses	-	3,003
	(466,850)	644,926

15 TAXES

15-1 Corporate taxes

- The Company's records were inspected for the years from inception till year 2004 and the taxes due were paid.
- No tax inspection took place for the Company's records for the years from 2005 till year 31 March 2017.

15-2 Salary Tax

- The Company's records were inspected from inception till year 2004 and the taxes due were paid.
- The Company's records were inspected for the years from 2005 till year 2011. The Company objected on the assessment and the issue is currently in the internal committee.
- No tax inspection took place for the Company's records for the years 2012 till year 31 March 2017.

15-3 Sales Tax - Value Added Tax

- The Company's records were inspected from inception till year 2015 and the taxes due were paid.
- No tax inspection took place for the company's records for the years 2015 till year 31 March 2017.

15-4 Stamp Tax

 No tax inspection took place for the company's records since inception till year 31 March 2017.

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

16 RELATED PARTY DISCLOSURES

For the purpose of these financial statements, parties are considered to be related to the Company, if the Company has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control. Related parties may be individuals or other entities.

Related party transactions

During the year, the following were the significant related party transactions, which were carried out in the normal course of business on terms agreed between the parties:

Company name	Nature of transaction	31/3/2018	31/3/2017
Sun Pharmaceutical Industries Limited		LE	LE
(India)	Purchase of raw materials	-	8,460
	Commission for importing raw and packing materials (Revenues)		
Cun Dhoman Fount		-	-
Sun Pharma Egypt Limited (Egypt)	Loan interest – Expenses Expenses charged from Sun Pharma Egypt Limited	220,318	220,318
	(Cross Charge Expenses)	234,370	1,518,560
	Imported raw materials for Sun Pharma Egypt Limited	-	-

The related parties' transactions described above resulted in the following balances:

a) Related party balances:

Due to related parties

	31/3/2018 LE	31/3/2017 LE
Current		
Sun Pharmaceutical Industries Limited (India)	632,455	1,317,337
Sun Pharma Egypt Limited	2,392,711	1,974,488
Sun Pharma Egypt Limited - (Loan accrued interest)	18,712	35,613
	3,043,878	3,327,438
Non Current		
Sun Pharma Egypt Limited (L.L.C) - (long term loan) *	2,173,000	2,173,000
	2,173,000	2,173,000

^{*}This amount represents a loan granted from Sun Pharma Egypt Limited (L.L.C) with an amount of L.E. 1,650,000 as per the contract dated 28 December 2009, with an annual fixed interest rate of 10%, and another loan amounted to L.E. 523,000 as per the contract dated June 2010, with an annual fixed interest rate of 10%.

NOTES TO THE FINANCIAL STATEMENTS 31 March 2018

17 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

Overview

The Company has exposure to the following risks from its use of financial instruments:

- a) Credit risk,
- b) Market risk, and
- c) Liquidity risk.

This note presents information about the Company's exposure to each of the above risks, the Company's objectives, policies and processes for measuring and managing risk, and the Company's management of capital.

The General Manager of the Company has overall responsibility for the establishment and oversight of the Company's risk management framework. The Company's senior management are responsible for developing and monitoring the risk management policies and report regularly to the Head Quarter on their activities.

The Company's current financial risk management framework is a combination of formally documented risk management policies in certain areas and informal risk management policies in other areas.

a) Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk principally from its receivables from customers, due from related parties, other receivables and from its financing activities, including deposits with banks and financial institutions.

Trade and notes receivables

The customer credit risk is established by the Company' policies, procedures and controls relating to customer credit risk management. Credit quality of a customer is assessed based on extensive credit rating scorecard and individual credit limits are defined in accordance with this assessment. Outstanding customer receivables are regularly monitored. An impairment analysis is performed at each reporting date on an individual bases.

Other financial assets and cash deposits

With respect to credit risk arising from the other financial assets of the Company, which comprise mainly bank balances and cash, the Company's exposure to credit risk arises from default of the counterparty, with a maximum exposure equal to the carrying amount of these assets.

Credit risk from balances with banks and financial institutions is managed by local Company's treasury supported by the Head Quarter. The Company limits its exposure to credit risk by only placing balances with international banks and local banks of good reputation. Given the profile of its bankers, management does not expect any counterparty to fail to meet its obligations.

Due from related parties

Due from related parties relates to transactions arising in the normal course of business with minimal credit risk, with a maximum exposure equal to the carrying amount of these balances.

b) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices, such as currency risk and interest rate risk, which will affect the Company's income. Financial instruments affected by market risk include interest-bearing loans and borrowings and deposits. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return. The Company does not hold or issue derivative financial instruments.

Exposure to interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's obligations with floating interest rates and interest bearing time deposits.

NOTES TO THE FINANCIAL STATEMENTS

31 March 2018

Interest on financial instruments having floating rates is re-priced at intervals of less than one year.

The following table demonstrates the sensitivity to a reasonably possible change in interest rates with all other variables held constant, of the Company's profit before tax (through the impact on floating rate borrowings). There is no impact on the Company's equity other than the profit impact stated below.

	3	31/3/2018		31/3/2017	
	Change in rate	Effect on profit before tax LE	Change in rate	Effect on profit before tax LE	
Financial asset	+1%	725	+1%	524	
	- 1%	(725)	- 1%	(524)	
Financial liability	+1%	(2,173)	+1%	(2,173)	
	- 1%	2,173	- 1%	2,173	

Exposure to foreign currency risk

The following tables demonstrate the sensitivity to a reasonably possible change in USD exchange rates, with all other variables held constant. The impact on the Company's profit before tax is due to changes in the value of monetary assets and liabilities. The Company's exposure to foreign currency changes for all other currencies is not material.

	31	31/3/2018		
	Change in rate	Effect on profit before tax LE		
USD	+10% -10%	(61,829) 61,829		

c) Liquidity risk

The cash flows, funding requirements and liquidity of the Company are monitored by local Company management supported by the headquarters The Company's objective is to maintain a balance between continuity of funding and flexibility using bank borrowings. The Company manages liquidity risk by maintaining adequate reserves and borrowing facilities, by continuously monitoring forecasted and actual cash flows and matching the maturity profiles of financial assets and liabilities.

The Company currently has sufficient cash on demand to meet expected operational expenses, including the servicing of financial obligations.

The table below summarises the maturity profile of the Company's financial liabilities based on contractual undiscounted payments.

NOTES TO THE FINANCIAL S 31 March 2018	TATEMENT	S			
Financial liabilities					
	Less than 3 Months	3 to 12 months	1 to 5 years	Over 5 years	Total
As at 31 March 2018					
Trade and other payables	4,469	-	-	2	4,469
Due to related parties	-	4,197,377	2,173,000	-	6,370,377
Total undiscounted financial liabilities	4,469	4,197,377	2,173,000		6,374,846
	Less than 3 Months	3 to 12 months	1 to 5 Years	Over 5 years	Total
As at 31 March 2017					
Trade and other payables	7,855	1,461		70	9,316
Due to related parties		10,375,070	2,173,000	-	12,548,070
Total undiscounted financial liabilities	7,855	10,376,531	2,173,000	-	12,557,386

18 FAIR VALUES OF FINANCIAL INSTRUMENTS

Financial instruments comprise financial assets and financial liabilities.

Financial assets of the Company include cash at banks, accounts and notes receivable, due from related parties, other receivables and other debit balances. Financial liabilities of the Company include interest-bearing loans and borrowings, accounts payable, accrued expenses and other payables, due to related parties.

The fair values of the financial assets and liabilities are not materially different from their carrying value unless stated otherwise.